Serum pentraxin-3 as a potential biomarker for diagnosis and prognosis in primary liver cancer: An observational study
Li Chen, Shifu Song, Mao Chen, Qin Liu, Hongchi Zhou · 2024
Read Serum pentraxin-3 as a potential biomarker for diagnosis and prognosis in primary liver cancer: An observational study by Li Chen, Shifu Song, Mao Chen, Qin Liu, Hongchi Zhou (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11651449.txt.
Description
Li Chen and four co-authors test a blood protein as a liver cancer flag in a 2024 study. Pentraxin-3 rises with inflammation, and the team asked whether it also tracks primary liver cancer closely enough to help clinics.
They drew blood from 180 patients and 180 healthy people and measured the protein with a standard kit. Levels ran clearly higher in patients, and higher still with drinking history, larger or more numerous tumors, spread stage, and vessel invasion. A cutoff sorted patients from healthy people fairly well, though not perfectly. Survival tracking linked high levels to worse outlook. The authors pitch the protein as a useful extra marker, not a lone verdict.
Catalog record
| CREATOR | Li Chen, Shifu Song, Mao Chen, Qin Liu, Hongchi Zhou |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |